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ABSTRACT
HDM2 is a p53-specific E3 ubiquitin ligase. Its
overexpression leads to excessive inactivation of
tumor protein p53, diminishing its tumor suppressor
function. HDM2 also affects the cell cycle, apoptosis
and tumorigenesis through interacting with other
molecules, including several ribosomal proteins.
To identify novel HDM2 regulators, we performed a
yeast two-hybrid screening using HDM2 as bait.
Among the candidates, ribosomal protein L26
(RPL26) was characterized as a novel HDM2-
interactor. The interaction between HDM2 and
RPL26 was further validated by in vivo and in vitro
assays. RPL26 modulates the HDM2–p53 interaction
by forming a ternary complex among RPL26, HDM2
and p53, which stabilize p53 through inhibiting the
ubiquitin ligase activity of HDM2. The ribosomal
stress caused by a low dose of Act D enhances
RPL26–HDM2 interaction and activates p53.
Overexpression of RPL26 results in activating of
p53, inhibits cell proliferation and induces a
p53-dependent cell cycle arrest. These results
provide a novel regulatory mechanism of RPL26 to
activate p53 by inhibiting HDM2.
INTRODUCTION
Tumor suppressor p53 is a transcription factor that acts
by stopping cell cycle progression or promoting apoptosis
when cells encounter stress stimuli such as oncogene acti-
vation or DNA damage (1). The importance of p53 in
cancer development is illustrated by the fact that p53 is
highly mutated in many diﬀerent cancers (2) and is
probably rendered inactive by a range of indirect
mechanisms (for example, HDM2 ampliﬁcation or loss
of ARF) in most other cancer types.
Having a short half-life, p53 is normally maintained at
low levels in unstressed mammalian cells by continuous
ubiquitination and subsequent degradation by the 26S
proteasome. This is primarily due to the interaction of
p53 with the RING-ﬁnger ubiquitin E3 ligase MDM2
(also known as HDM2; 3). The mdm2 gene is one of the
target genes the transcription of which is activated by the
p53 proteins, thus forming a tight auto-regulatory
feedback loop (4,5).
The ability of HDM2 to keep p53 in check is essential
for normal cell function. The repression operates via three
mechanisms. First, HDM2 interacts with the N-terminal
transactivation domain of p53, which is the primary
binding site for HDM2. Through binding to p53 at its
transactivation domain, HDM2 inhibits p53 transcrip-
tional activity (4). Second, HDM2 labels p53 with ubiqui-
tin for degradation (6). Lastly, HDM2 is responsible for
the export of p53 from nucleus to cytoplasm to abrogate
its transcriptional activity (7). Many cellular stresses such
as DNA damage stabilize p53 protein by blocking the
HDM2–p53 feedback loop (8). One prominent example
is that, in response to oncogene activation, p14ARF acti-
vates p53 by inhibiting the ubiquitin ligase activity of
HDM2 and relieving HDM2-dependent inhibition of
p53 (9).
Besides ARF, a number of factors that alter the p53–
HDM2 feedback loop have been identiﬁed, including the
retinoblastoma protein (Rb) and the transcription factor
Yin Yang 1 (YY1). Nucleolar proteins are also prominent
among this group, including the ribosomal proteins L5,
L11, L23, S7 (10–14), PML (15) and nucleophosmin
(also called B23). Ribosomal proteins L5, L11, L23 and
S7 interacted with HDM2 and inhibited the HDM2–p53
feedback loop in response to ribosomal stress, such as
treatment with low dose actinomycin D (Act D), serum
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treatment (17). Thus, releasing small protein molecules
such as the ribosomal proteins from the nucleolus leads
to p53 activation in response to ribosomal stress.
In this study, we designed to search for novel
HDM2-binding proteins. We conducted stringent yeast
two-hybrid (Y2H) screening using full-length HDM2 to
screen human liver cDNA library. RPL26 was a novel
ribosomal protein that can directly interact with HDM2,
and its interaction with HDM2 was conﬁrmed in vivo and
in vitro. Furthermore, RPL26 modulates the HDM2-p53
interaction by forming a ternary complex among RPL26,
HDM2 and p53, which leads to the stabilization of p53
and HDM2 by inhibiting the ubiquitin ligase activity of
HDM2. RPL26 activates p53 by overcoming
HDM2-mediated p53 degradation through the prote-
asome. The interaction of RPL26 and HDM2 was
increased and activated p53. Overexpression of RPL26
results in activating of p53, inhibits cell proliferation and
induces a p53-dependent cell cycle arrest. From previous
report, RPL26 was found to bind to the 50 untranslated
region (UTR) of p53 mRNA and control p53 translation
and induction after DNA damage (18). Thus, RPL26 is
the only identiﬁed ribosomal protein that activates p53 by
simultaneously potentiating its translation and
attenuating its degradation till now. These observations
provide an additional regulatory mechanism associated
with RPL26 in regulating p53 function.
MATERIALS AND METHODS
Cell culture
Human embryonic kidney HEK293, human osteosarcoma
U2OS cells, mouse p53
 / /mdm2
 /  MEF cells and
HCT116 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10%(v/v)
fetal bovine serum, and Human lung small cell adenocar-
cinoma H1299 cells were maintained in RPMI medium
1640 with 10% FBS.
Plasmids and reagents
The pCMV-p53, pCMV-HDM2, and pcDNA3/
poly-HA-tagged ubiquitin were kindly provided by Dr
Y. Xiong, (University of North Carolina, Chapel Hill,
NC, USA), and pG13-Luc were obtained from Dr B.
Vogelstein (Johns Hopkins Medical Institutions,
Baltimore, MD, USA). Various constructs of RPL26
were generated according to standard molecular tech-
niques. All deletion mutants were created by polymerase
chain reaction (PCR) to obtain DNA fragments and sub-
jected to sequencing veriﬁcation. The details of the primer
sequences used for deletion mutations are available upon
request. The proteasome inhibitor MG132 and protein
synthesis inhibitor cycloheximide (CHX) were purchased
from Sigma (St Louis, MO, USA). Anti-FLAG and
RPL26 antibody were purchased from Sigma (St Louis),
anti-HA antibody from Roche (Basel, Switzerland),
anti-Myc, anti-Flag-HRP, anti-GFP and anti-HDM2
antibody were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
Yeast two-hybrid screening
The two-hybrid screening was performed with the
ProQuest
TM
two-hybrid system (Invitrogen, CA, USA).
Full length human HDM2 was cloned in-frame with the
GAL4 DNA binding domain in the vector pDBLeu to
create pDBLeu-HDM2. MaV203 yeast cells were succes-
sively transformed with pDBLeu-HDM2 and human liver
cDNA library. A total of  1 10
6 independent
transformants were analyzed and clones were selected
for positive interactions based on screening for expression
of reporter genes His3, LacZ and URA3. To eliminate
interactions that originated from nonspeciﬁc promoter ac-
tivation, we only considered DB-HDM2-AD-Prey pairs if
they activated at least two out of three reporter genes.
Positives were subsequently retested in fresh yeast cells,
and their AD-Prey identities were determined with inter-
action sequence tags (ISTs) obtained by sequencing. The
AD-Prey reading frame was veriﬁed for each IST to avoid
the recovery of out-of-frame peptides.
Transfection, immunobloting and immunoprecipitation
analyses
H1299, U2OS, MEF, HCT116 or HEK293 cells were
transfected with plasmids as indicated in each ﬁgure
legend using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. Cells were harvested
at 24h post-transfection and lysed in HEPES lysis buﬀer
[50mM Tris–HCl (pH 7.5), 150mM NaCl, 1% (v/v)
Tween 20, 0.2% NP-40, 10% glycerol] supplemented
with protease inhibitor cocktail (Roche, Basel,
Switzerland) and phosphatase inhibitors (10mM NaF
and 1mM Na3VO4). Immunoprecipitation and immuno-
blotting analysis were performed as described previously
(19).
In vitro GST pull-down assays
Bacteria-expressed GST or GST–HDM2 proteins were
immobilized on glutathione-Sepharose 4B beads (GE,
UK) and washed, and then beads were incubated with
His-RPL26 expressed in Escherichia coli BL21 and
puriﬁed with Ni-nitrilotriacetate-agarose beads (GE,
UK) for 3h at 4 C. Beads were washed with GST
binding buﬀer (100mM NaCl, 50mM NaF, 2mM
EDTA, 1% Nonidet P40 and protease inhibitor cocktail)
and proteins were eluted, followed by western blotting.
Immunoﬂuorescent staining
U2OS cells were transfected with GFP-RPL26 and
HDM2 expression plasmid. Twenty-four hours after
transfection, cells were ﬁxed with 5% paraformaldehyde
for 30min and permeabilized in 0.2% Triton X-100 (PBS).
Then cells were incubated with mouse anti-HDM2
(dilution 1:50; Santa Cruz) for 1h, followed by incubation
with TRITC-conjugated secondary antibody 1h at room
temperature. Nuclei were stained with 100mg/ml
4,6-diamidino-2-phenylindole. Images were visualized
with a confocal microscope.
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Luciferase reporter plasmids pG13-Luc and pRL-CMV
(Promega) were cotransfected with plasmids indicated in
ﬁgures. After 24h, cells were lysed and measured for
luciferase activity with the Luciferase Assay System
(Promega) according to the manufacturer’s protocol.
In vivo ubiquitination assays
H1299 cells (60% conﬂuence, 100-mm diameter plate)
were transfected with plasmids expressing HA-ubiquitin
(2mg), Flag-p53 (2mg), Myc-RPL26 (2mg) or HDM2
(2mg) in various combinations. At 48h after transfection,
cells from each plate were harvested and split into two
aliquots, one for western blotting and the other for
ubiquitination assays. Cell pellets were lysed in HEPES
lysis buﬀer (0.02M HEPES, 0.05M NaCl,1mM
Triton-100, 1mM NaF, 1mM DTT, 1mM Na3VO5)
and incubated with HA antibody at 4 C for 2h, then
incubated with protein A/G-sepharose (Santa Cruz) for
8h. Sepharoses were washed three times with lysis
buﬀer. And they were analyzed by western blotting with
indicated antibodies.
siRNA experiments
Cells were transfected with 100nmol RPL26 siRNA
complex or a scrambled control (UUCUCCGAACGUG
UCACGUTT) and other plasmids showed in ﬁgures. The
RPL26 siRNA complex contained three siRNA se-
quences. They are CCGAAAGGAUGAUGAAGU
UTT(18), CACAUUCGAAGGAAGAUUATT and AG
GUUGUACGUGGACACUAUATT. After 24h, cells
were washed with phosphate-buﬀered saline, lysed
directly into sample buﬀer and resolved by 12% SDS–
polyacrylamide gel electrophoresis.
Cell proliferation assays
For assessing the eﬀect of RPL26 expression on growth
rate, cells were cultured into 96-well plates in triplicate for
24h. Then U2OS or H1299 cells were transiently trans-
fected with indicated plasmid or siRNA. After 24h
post-transfection, cell proliferation was measured by the
MTS-based cell proliferation assay. The experiment was
performed on three independent occasions in triplicate.
Cell cycle analysis
Cells were transfected with plasmids encoding GFP,
GFP-RPL26. At 24h post-transfection, cells were har-
vested by trypsinization, ﬁxed in 70% ethanol and
stained with propidium iodide (50mg/ml) containing
1mg/ml of RNase A at 37 C for 30min and then
analyzed for DNA content. At least 10000 GFP-positive
cells were gated for cell cycle analysis.
RESULTS
RPL26 interacts with HDM2 in vitro and in vivo
To search for novel binding partners of HDM2, we con-
ducted stringent Y2H screening using full-length HDM2
as bait. Three ribosomal proteins L11, S7 and L26 were
identiﬁed as candidate HDM2 interacting proteins.
RPL11 (20) and RPS7 (14) have previously been shown
to bind to HDM2, while RPL26 has been found to bind to
the 50UTR of p53 mRNA and augment its translation and
induction after DNA damage (18). We retested the inter-
action between HDM2 and RPL26 by yeast
retransformation assay. The yeast colonies that contained
DNA binding (DB)-HDM2 and activating domain (AD)-
RPL26 simultaneously activated the two reporter genes
(HIS3 and URA3; Figure 1A).
To further conﬁrm the association of HDM2 and
RPL26 in mammalian cells, we expressed Myc-tagged
RPL26 and untagged HDM2 individually or together in
HEK293 cells followed by co-immunoprecipitation (CoIP)
analysis with either anti-Myc or anti-HDM2 antibodies.
Indeed, HDM2 speciﬁcally immunoprecipitated with
RPL26 by anti-Myc antibody when expressed with
HDM2 (Figure 1B, lane 6). Conversely, RPL26 also spe-
ciﬁcally co-immunoprecipitated with HDM2 by
anti-HDM2 antibody (Figure 1C, lane 6). In contrast,
there was no HDM2 or RPL26 detected in Myc or
HDM2 antibody immunoprecipitates from cells trans-
fected with Myc-RPL26 alone or HDM2 alone.
Consistently, the direct physical binding between HDM2
and RPL26 was demonstrated by in vitro pull-down assay.
As shown, GST-HDM2, but not GST, bound to
His-RPL26 expressed in E. coli BL21 and puriﬁed with
Ni-nitrilotriacetate agarose beads (Figure 1D, lane 4).
Moreover, the binding of endogenous HDM2 and
RPL26 was conﬁrmed in MCF7 cells with anti-HDM2
antibody. Western blotting analysis showed that the
HDM2 immunoprecipitate contained RPL26 (Figure 1E,
lane 3). To determine the subcellular position of the
RPL26-HDM20s binding in cells, the U2OS cells were
transfected with GFP-RPL26 and HDM2. As shown in
Figure 1F, HDM2 and RPL26 were co-localized in nu-
cleoplasm. All these results indicate that HDM2 direct
binds to RPL26 under normal cellular conditions.
Determination of mutual interaction regions in HDM2
and RPL26
To determine the interacted region of HDM2 and RPL26,
series deletion mutants were constructed, as indicated
schematically (Figure 2A and 2C). When co-transfected
with Myc-HDM2, the full-length RPL26 was
co-immunoprecipitated with Myc-HDM2 (Figure 2B,
lower panel, lane 9), while RPL26 was not observed in
the control lane (Figure 2B, lower panel, lane 8). HDM2
deletion mutants B, C and E retained their ability to form
a complex with RPL26 (Figure 2B). However, HDM2
deletion mutants A and D lost their ability to interact
with RPL26 (Figure 2B), indicating that the region
around amino acids (aa) 204–345 in HDM2 is critical
for RPL26 interaction.
We co-transfected diﬀerent deletion mutants of RPL26
with the full-length HDM2 to HEK293 cells to deﬁne the
binding region of RPL26 with HDM2. As shown in
Figure 2D, all the RPL26 mutants, with the exception of
A and D, interacted with HDM2, indicating that the
6546 Nucleic Acids Research, 2010,Vol.38, No. 19region spanning aa 45–100 of RPL26 is critical for HDM2
interaction (Figure 2D). While the central domain of
RPL26 contains aa 63–90 is also particularly important
in regulation of p53 translation (18).
RPL26 enhances p530s stability and activity by
overcoming HDM2-mediated suppression
HDM2, a p53-speciﬁc E3 ubiquitin ligase, is the principal
cellular antagonist of p53. Disruption of the p53–HDM2
interaction by multiple regulators is the pivot event for
p53 activation, leading to p53 induction and its biological
response. To investigate the functional consequences of
RPL26–HDM2 interaction, we examined whether
RPL26 could aﬀect the function of HDM2 in degrading
p53 and p53-dependent transcription. The p53-posivite
U2OS cells were transfected with Myc-RPL26 or
untagged-HDM2 together with a luciferase reporter
plasmid which containing a consensus p53 target
sequence. Ectopic expression of full-length RPL26
Figure 1. RPL26 binds to HDM2. (A) HDM2 binds RPL26 in yeast two hybrid assays. A collection of yeast control strains, from A to E, have been
developed that contain plasmid pairs expressing fusion proteins with a spectrum of interaction strengths from none, weak, moderately strong, strong
to very strong. Transformants with indicated plasmids were cultured on SC-Trp-Leu-His-Ura plates and incubated at 30 C for 3–4 days. (B and C)
Exogenous HDM2 and RPL26 interact with each other in HEK293 cells. HDM2 (3mg), Myc-RPL26(3mg) or both vectors (3mg) were used for
transfection. Whole-cell lysates were subjected to immunoprecipitation with anti-HDM2 or anti-Myc antibodies followed by immunoblotting with
anti-Myc or anti-HDM2 antibodies. IP, immunoprecipitation; IB, immunoblotting; Lys, lysate; HC, heavy chain. LC, light chain. (D) Direct
interaction between RPL26 and HDM2 revealed by GST pull-down assays. Both input and pull-down samples were subjected to immunoblotting
with anti-His and anti-GST antibodies. (E) Binding between endogenous HDM2 and RPL26 in MCF7 cells. The lysates of MCF7 cells were
immunoprecipitated with nonimmune mouse IgG or an antibody against HDM2. The immunoprecipitates were further separated by SDS–
PAGE, and target proteins were detected with RPL26 and HDM2 antibodies. Ig, immunoglobulin. Asterisk indicates non-speciﬁc band.
(F) HDM2 colocalized with RPL26 in the nucleoplasm. U2OS cells were transfected with GFP-RPL26 and HDM2. Scale bar, 10mm.
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activity, as presented as luciferase activity, in a dose-
dependent manner (Figure 3A).
All of the reported ribosomal proteins that interact with
HDM2 can activate p53 through inhibiting HDM2.
RPL26 might adopt similar mechanisms. As RPL26
binds to the 50UTR of p53 mRNA and eﬀects the trans-
lation of p53 (18), we examined overexpression of
RPL260s eﬀect on HDM2-mediated p53 degradation by
introducing exogenous proteins into p53-deﬁcient human
non-small-cell carcinoma H1299 cells. Plasmids expressing
HDM2, Flag-tagged p53, and Myc-tagged RPL26 were
transfected to H1299 cells, and the expression of p53
was under the control of CMV promoter that did not
contain the 50UTR of p53. As expected, overexpression
of HDM2 remarkably reduced p53 levels (Figure 3B). In
contrast, overexpression of RPL26 rescued HDM2-
mediated p53 degradation in a dose-dependent fashion
(Figure 3B).
That the RPL26 activates p53 by inhibiting HDM2 was
further validated in MEF (p53
 / /mdm2
 / ) cells. The
p53-dependent reporter was cotransfected in combin-
ations with HDM2, Myc-tagged p53, Myc-tagged
RPL26 and siRNA as indicated. HDM2 and RPL26 did
not aﬀect p53 transcription activity without p53 in MEF
(p53
 / /mdm2
 / ) cells (Figure 3C, lane 1 to 3). RPL26
did not directly aﬀect the exogenous p53 transcription
activity in MEF (p53
 / /mdm2
 / ) cells (Figure 3C, lane
4 and 5). In contrast, expression of HDM2 inhibited the
exogenous p53 transcriptional activity, and co-expression
of RPL26 alleviated exogenous HDM2-mediated p53 sup-
pression in the MEF (p53
 / /mdm2
 / ) cells (Figure 3C,
lane 6 and 7). Conversely, knockdown of RPL26 had no
measurable eﬀect on the exogenous p53 transcriptional
activity while lacking HDM2 (Figure 3D, lane 2 and 3)
in the MEF (p53
 / /mdm2
 / ) cells. But knockdown of
RPL26 did not give notable eﬀect on the exogenous p53
transcriptional activity with HDM2 in the MEF (p53
 / /
mdm2
 / ) cells (Figure 3D, lane 4 and 5). Knockdown of
RPL26 reduced HDM20s expression level. These results
demonstrated that RPL26 stimulates p53-dependent tran-
scription by inhibiting the activity of HDM2.
RPL26 attenuates HDM2-mediated ubiquitination
and degradation
As we know, HDM2 is a RING-ﬁnger ubiquitin E3 ligase
(3). HDM2-dependent suppression of p53 may be related
with its E3 ligase activity on p53 (6). To determine
whether RPL26 stabilize p53 by aﬀecting HDM2-
mediated ubiquitination and degradation, we did an
in vivo ubiquitination assay. Overexpression of RPL26
not only led to marked inhibition of p53 ubiquitination
(Figure 4A, lane 4 and 5) but also stabilized HDM2
(Figure 4B, lane 4 and 5). The ability of RPL26 to
inhibit HDM2-induced p53 degradation could be ex-
plained by its inhibiting of HDM2-mediated p53
polyubiquitination.
To further determine if RPL26 acts on HDM2 and p53
at the post-translational level, plasmids expressing
HDM2, GFP and RPL26 were co-expressed in U2OS
Figure 2. Determination of mutual interaction regions in HDM2 and
RPL26. (A) A diagram for the deletion mutants of HDM2 is shown.
(B) Mapping of the HDM2 domain for RPL26 binding. Extracts from
HEK293 cells transfected with the indicated plasmid DNA encoding
deletion mutants of HDM2 and Flag-RPL26 were immunoprecipitated
with Myc antibody, and followed by immunoblotting with Flag or Myc
antibodies. (C) A diagram for the deletion mutants of RPL26 is shown.
(D) Mapping of the RPL26 domain for HDM2 binding. Extracts from
HEK293 cells transfected with the indicated plasmid DNA encoding
deletion mutants of RPL26 and HA-HDM2 were immunoprecipitated
with HA antibody, and followed by immunoblotting with HA and Myc
antibodies.
6548 Nucleic Acids Research, 2010,Vol.38, No. 19cells as indicated, which were then exposed to the protein
synthesis inhibitor, cycloheximide, for diﬀerent times
(Figure 4C). The p53 protein did not show apparent dif-
ference in RPL26 transfected cells. The level of p53
protein decreased when transfected with HDM2, but it
can be rescued by the expression of RPL26. Compared
to the control, the degradation of HDM2 protein was
much more slowly in RPL26 transfected cells. The
results suggest that RPL26 aﬀect HDM2 and p53 at the
post-translational level. The RPL26 might inhibit
HDM20s E3 ligase function, while HDM2 harbors a self-
and p53-speciﬁc E3 ubiquitin ligase activity (6).
Furthermore, the binding of RPL26 and HDM2 seems
to be crucial for this process. In MEF (p53
 / /mdm2
 / )
cells which were overexpressed with diﬀerent mutants of
RPL26 plasmids, RPL26 mutants did not aﬀect the p53
level without HDM2 (Figure 4E, left panels). But RPL26
mutants retaining the capacity for binding to HDM2 (B, C
and E) stabilized p53 and HDM2, while those without
binding capacity, A and D, did not increase the p53 and
HDM2 levels in MEF (p53
 / /mdm2
 / ) cells which were
co-transfected with HDM2 (Figure 4E, right panels). It
demonstrated that the HDM2 binding capacity of
RPL26 was pivot for the regulation of HDM2-dependent
degradation.
To explore the relationship of RPL26, HDM2 and p53,
HEK293 cells were transiently transfected with various
combinations of plasmids (Figure 4F). As shown,
Flag-p53 was detected in Myc-RPL26 immunoprecipitates
of lysates from cells only transfected with Myc-RPL26
and Flag-p53 (Figure 4F, lane 7), albeit with lower
aﬃnity compared to the presence of HDM2 (Figure 4F,
lane 8). The result illustrates the formation of a complex
among RPL26, HDM2 and p53, while p53 and RPL26
can immunoprecipitated in a complex without
HDM2. Together, RPL26 decreases HDM2-mediated
Figure 3. RPL26 enhances p530s stability and activity by overcoming HDM2-mediated suppression. (A) Ectopic expression of RPL26 increases
p53-dependent transactivation from the pG13-Luc reporter in p53-positive U2OS cells. U2OS cells were transfected with increasing amounts of
Myc-RPL26 [0.4mg( 1  ) and 0.8mg( 2  )] in the presence or absence of ectopically expressed HDM2 (0.2mg). After 28h, the luciferase assay was
performed. Data are plotted as mean±standard errors for three independent experiments. (B) Ectopic expression of RPL26 reverses
HDM2-mediated p53 degradation. H1299 cells were transfected with Myc-RPL26 (0.2mg or 0.4mg) in the presence of p53 (0.1mg) with ( )o r
without (+) HDM2 (0.4mg) as indicated. Cell lysates were immunoblotted with anti-HDM2, anti-Myc, anti-Flag or anti-actin antibodies.
(C) Expression of RPL26 alleviated exogenous HDM2-mediated p53 suppression in the MEF (p53
 / /mdm2
 / ) cells. MEF (p53
 / /mdm2
 / )
cells were transfected with ( ) or without (+) Myc-RPL26 (0.4mg) in the presence or absence of ectopically expressed HDM2 (0.2mg). After 24h, the
luciferase assay was performed. Data are plotted as mean ± standard errors for three independent experiments. Inset shows similar expression levels
of relevant transfected proteins. (D) Knockdown of RPL26 did not inhibit p53 in cooperation with HDM2 in MEF (p53
 / /mdm2
 / ) cells. MEF
(p53
 / /mdm2
 / ) cells were transfected with or without RPL26 siRNA (100nM) in the presence or absence of ectopically expressed p53 (0.1mg) or
HDM2 (0.4mg). After 24h, the luciferase assay was performed. Data are plotted as mean±standard errors for three independent experiments.
Nucleic Acids Research, 2010,Vol.38, No. 19 6549Figure 4. RPL26 attenuates HDM2-mediated ubiquitination and degradation. (A and B) RPL26 inhibits HDM2-mediated p53 and HDM2
ubiquitination in H1299 cells. H1299 cells were transfected with combinations of RPL26 (2mg)-, p53 (1mg)- or HDM2 (2mg)-encoding plasmids
in the presence of the HA-ubiquitin (HA-Ub) (2mg) plasmid as indicated. The cells were treated with MG132 (20mM) for 8h before harvesting. The
cell extracts was immunoprecipited by Flag antibody (A) or HDM2 antibody (B). Ubiquitinated proteins were detected by immunoblotting with
the anti-HA antibodies. Ubiquitinated p53s [p53-(HA-Ub)n] (A) or Ubiquitinated HDM2s [HDM2-(HA-Ub)n] (B) is indicated to the upper panels.
The expression levels of HDM2, p53 and L26 are shown in the lower panels. (C) Half-life analysis of p53 and HDM2 in the presence or absence of
overexpressed RPL26. U2OS cells were transfected with 0.2mg of Myc-RPL26 in the presence of GFP (50ng) with ( ) or without (+) HDM2 (0.4mg)
Continued
6550 Nucleic Acids Research, 2010,Vol.38, No. 19ubiquitination and degradation of p53 and HDM2 by
binding to HDM2.
Act D enhances RPL26-HDM2 interaction and
activates p53
It has been demonstrated that, a low dose of Act D (5nM)
speciﬁcally inhibits RNA polymerase I and consequently
reduces rRNA synthesis, leading to perturbation of ribo-
somal biogenesis (21). Some ribosomal proteins, including
L5, L11, L23 and S7, are released and modulate the
HDM2–p53 interaction. We examined the level of
RPL26 with diﬀerent dose of Act D. As shown in
Figure 5A, the level of RPL26 was decreased a little by
treatment with high dose of Act D. With the low dose of
Act D, the level of RPL26 did not apparently change, but
the level of p53 enhanced time-dependently (Figure 5B).
We examined the binding of HDM2, RPL26 and p53,
with treatment of 5nM Act D. The level of p53 and
HDM2 enhanced a lot (Figure 5C, left panel) and the
endogenous binding between RPL26 and HDM2 was
increased (Figure 5C, right panel). It might due to the
formation of a complex among RPL26, HDM2 and p53
following the release of RPL26 in response to ribosomal
stress.
To determine if RPL26 is necessary for p53 induction
caused by Act D, U2OS cells were transfected transiently
with RPL26 siRNA or control siRNA prior to treatment
with 5nM of Act D. As shown in Figure 5D, the expres-
sion level of RPL26 was decreased after RNAi. While the
protein level of p53 and HDM2 also drastically decreased.
The results suggest that knockdown of RPL26 inhibit Act
D induced p53 levels. Moreover, knockdown of RPL26
inhibited the expression level of HDM2 with the treatment
of 20mM MG132, but did not aﬀect the protein level of
p53 (Figure 5D, lane 6 and 8). These results suggest that
RPL26 might aﬀect the stabilization of HDM2 and p53 by
inhibiting the ubiquitin ligase activity of HDM2.
RPL26 inhibits cell proliferation and induces cell cycle
arrest by p53
To investigate the cellular consequences of overexpresion
RPL26, we transfected Myc-RPL26 or control vector into
U2OS or H1299 cells. Such overexpression of Myc-RPL26
resulted in the inhibition of cell proliferation in U2OS cells
which contains functional p53 (Figure 6A). But RPL26
did not aﬀect the cell proliferation in H1299 cells which
is deﬁcient of p53 (Figure 6A). So RPL26 can regulate cell
proliferation by mediating p53 activity.
To test the eﬀect of siRNA knockdown of RPL26 on
cell proliferation, U2OS cells were transfected transiently
with RPL26 siRNA or control siRNA prior to treatment
with 5nM of Act D. As shown in Figure 6B, Act D
decreased the cell proliferation, while knockdown of
RPL26 increased the cell proliferation with or without
Act D.
Next, we examined whether activation of p53 by RPL26
could result in cell cycle distribution change. The
p53-proﬁcient U2OS or p53-deﬁcient H1299 cells were
transiently transfected with either the GFP-RPL26 or
the GFP. GFP-positive cells were then gated for cell
cycle analysis. As shown in Figure 6C, overexpression of
GFP-RPL26 induced cell cycle arrest only in U2OS, but
not in H1299 cells. To role out the inﬂuence of the genetic
alterations in cell types, the experiments were repeated in
the HCT116
+/+ (p53 positive) and HCT116
 /  (p53
negative) cells. Overexpression of RPL26 induced signiﬁ-
cantly cell cycle arrest in p53-positive cells than in negative
cells (Figure 6D).
DISCUSSION
RPL26 is one of the ribosomal proteins in 60S ribosome.
Previous report suggest that RPL26 may bind to 50UTR
of p53 mRNA and control p53 translation and induction
after DNA damage (18). In this study, we identify
that RPL26 regulate p53 protein level by physical inter-
acting with HDM2. Unlike reported HDM2 interactors,
RPL26 is the ﬁrst ribosomal proteins that can regulate
p53 activity at both translational and post-translational
level.
As far as we know, several ribosomal proteins L5, L11,
L23 and S7 have been shown to regulate p53 activity via
binding to HDM2 and blocking HDM2-mediated p53
ubiquitination and degradation (10–14). Further studies
suggest that ribosomal proteins that can bind to HDM2
may regulate HDM2–p53 pathway in a cooperative way
by forming a ribosomal proteins–HDM2–p53 complex
(10,22). Our data demonstrated that RPL26 also can
interact with HDM2 and form a complex with HDM2–
p53 (Figures 1 and 4F), but further studies will be needed
to illustrate the interrelationship of RPL26 and other ribo-
somal proteins in regulating p53 activity. Although these
ribosomal proteins can block HDM2-p53 loop in response
to ribosomal stress, the expression level of them changed
in a diﬀerent way in response to stress, such as
5-ﬂuorouracil (5-FU) or low dose Act D treatment
(13,16). We also detected the RPL26 expression level in
response to low-dose Act D treatment (Figure 5), and it
changed diﬀerently from other ribosomal proteins. The
expression level of RPL26 by Act D is dosage dependent.
It was decreased sharply after treatment of U2OS cells
with 50nM Act D. But the expression level of RPL26 by
a low dose of Act D is not timely dependent. While the
change of p53 level is not only eﬀected by the dose of Act
D but also the working time of low dose of Act D. These
Figure 4. Continued
as indicated. After 24h transfection, cells were exposed to the protein synthesis inhibitor CHX (100mg/ml) for diﬀerent times. Target proteins were
detected by immunoblotting. (D) Plot of the p53 and HDM2-expression levels following CHX treatment. The value is normalized to the levels of
GFP. (E) RPL26 modulates p53 by interacting with HDM2. Wild-type and mutant RPL26 were overexpressed in MEF (p53
 / /mdm2
 / ) cells with
or without HDM2 in the presence of p53, and the target proteins in whole-cell lysates were detected by immunoblotting. (F) RPL26 modulates the
HDM2–p53 interaction by forming a ternary complex among RPL26, HDM2 and p53. HEK293 cells were transfected with combinations of
plasmids as indicated. Cell lysates were immunoprecipitated by Myc antibody followed by immunoblotting with Myc, Flag-HRP, HDM2 and
b-actin antibodies for the immunoprecipitates or the whole-cell lysates.
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lating free ribosomal proteins response to perturbation.
Moreover, our data show that the HDM2 protein level
increased in U2OS cells when RPL26 overexpressed
(Figure 4C). It suggests that the increase of HDM2
is related to the decreasing of HDM20s E3 ubiquitin
ligase activity, not to the p53 transactivation of hdm2
gene. This phenomenon must be induced by the inter-
action of RPL260s binding to the central region of
HDM2 which contains nuclear localization, export se-
quences and a zinc-ﬁnger domain. In the context of
cancer-associated mutations in the HDM2 zinc-ﬁnger
domain disrupt ribosomal protein interaction and attenu-
ate HDM2-induced p53 degradation (23), ribosomal
proteins’ binding to HDM2 is an important mechanism
in regulating p53.
RPL26 induces p53 through direct binding to HDM2
and decreasing HDM20s ubiquitin E3 ligase activity. This
mode is diﬀerent from the previous reported mechanism
that RPL26 enhances p53 mRNA’s translation and ex-
pression level. But both mechanisms could improve
p530s level and activity and involve the middle domain
of RPL26 which can bind to HDM2 and 50UTR of p53
mRNA (18). This suggests that the two mechanisms might
operate together in regulating p53 by RPL26. Recently,
HDM2 has been reported to attenuate the association of
RPL26 with p53 mRNA and repress RPL26-mediated
augmentation of p53 protein synthesis by promoting
RPL260s proteasome-mediated degradation and binding
of RPL26 (24). Together, the interaction of RPL26 and
HDM2 seems to have mutual action that adjusts HDM2
and RPL260s eﬀecting on p530s expression level and
activity. These suggest that RPL26 and p53 may competi-
tively bind to HDM2. In this regard, the cancer-associated
mutations in RPL26 gene that inhibit its interaction with
50UTR of p53 mRNA or HDM2 are strong evidence of
RPL260s importance in cancer. Moreover, previous study
identiﬁed mutations in RPL26 in two murine tumor cell
lines resulting in a unique tumor-associated antigen and a
more aggressive tumor phenotype (25). Therefore, RPL26
might be a tumor suppressor that works by regulation
HDM2–p53 loop.
To sum up, we establish that RPL26 has the capacity
to stabilize p53 by binding to HDM2. Diﬀerent from
other HDM2 binding ribosomal proteins, RPL26 is the
only identiﬁed ribosomal protein that can activate p53
by simultaneously potentiating its translation and
attenuating its degradation till now. It would be important
to further investigate the roles of RPL26 in p53-related
cancer.
Figure 5. Act D enhances RPL26-HDM2 interaction and activates p53. (A) Low doses of Act D induce p53, whereas high doses of Act D inhibit
p53. U2OS cells were treated with increasing amounts of Act D (Act D) as indicated at the top. Cell lysates were used for an immunoblot analysis
with antibodies indicated to the left. (B) Time-dependent eﬀect of Act D on p53 and RPL26 levels in U2OS cells. U2OS cells were treated with 5nM
Act D and harvested at diﬀerent time points as indicated at the top. Cell lysates were used for an immunoblot analysis with antibodies indicated to
the left of each panel. (C) Low dose of Act D enhances HDM2–RPL26 interaction. U2OS cells were treated with ( ) or without (+) 5nM Act D for
24h before harvesting. (D) Inhibition of endogenous RPL26 by siRNA inhibits the Act D-induced p53 levels but did not eﬀect the protein level of
p53 with the treatment of MG132. U2OS cells were transfected with or without RPL26 siRNA (100nM). Cells were then incubated with ( )o r
without (+) 5nM Act D for 12h before harvesting. Cells were incubated with ( ) or without (+) MG132 (20mM) for 8h before harvesting. Cell
lysates were then immunoblotted with anti-HDM2, anti-p53, anti-RPL26 or anti-actin antibodies.
6552 Nucleic Acids Research, 2010,Vol.38, No. 19Figure 6. RPL26 enhances the activities of p53. (A) RPL26 inhibits a p53-dependent cell’s proliferation. U2OS and H1299 cells were transiently
transfected with Myc-RPL26 or Myc cells. After 24h post-transfection, cell proliferation was measured by the MTS-based cell proliferation assay.
Data are plotted as mean ± standard errors for three independent experiments. (B) siRNA knockdown of RPL26 increases U2OS cell’s prolifer-
ation. U2OS cells were transfected transiently with RPL26 siRNA or control siRNA. After 12h post-transfection, cell was treated with 5nM of Act
D for 12h. Then cell proliferation was measured by the MTS-based cell proliferation assay. Data are plotted as mean±standard errors for three
independent experiments. (C) RPL26 induces a p53-dependent cell cycle arrest. U2OS or H1299 cells were transfected with the indicated plasmid
expressing a GFP or GFP-RPL26 proteins. Transfected cells were sorted, and their cell cycle distribution characteristics were determined by
ﬂow cytometry at 24h after transfection. The proportions of cells in S phase in each transfected cell population were compared using bar
graphs. A minimum of 10 000 GFP-positive cells were analyzed for each transfection. (D) RPL26 induces a p53-dependent cell cycle arrest.
HCT116
+/+(p53-positive) and HCT116
 / (p53-negative) cells were transfected with the indicated plasmid expressing a GFP or GFP-RPL26
proteins. Transfected cells were sorted, and their cell cycle distribution characteristics were determined by ﬂow cytometry at 24h after transfection.
The proportions of cells in S phase in each transfected cell population were compared using bar graphs. A minimum of 10000 GFP-positive cells
were analyzed for each transfection.
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